Daiichi Sankyo/AstraZeneca Get Two Lucky Breaks For Enhertu
Executive Summary
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
You may also be interested in...
Enhertu Is First ADC Approved For Tumor-Agnostic Indication
The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.
AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
Read-Outs To Look Out For At ESMO Cancer Congress
The European cancer congress returns in-person, with companies big and small presenting new agents and combinations across tumor types.